文献速递胃肠外科

内镜黏膜下剥离术在超扩大适应证早期胃癌中的适用性

Applicability of endoscopic submucosal dissection for patients with early gastric cancer beyond the expanded indication for endoscopic submucosal dissection.
PubMed 文献 · Surg Endosc · 2022-05-11

本研究回顾性分析了673例术前评估超出内镜黏膜下剥离术(ESD)扩大适应证而接受胃切除术的早期胃癌患者,发现39%术后病理为内镜治愈性A或B级,可仅通过ESD治愈。多因素分析显示肿瘤≤10mm、无溃疡、分化型组织学及位于胃远端三分之二为独立预测因素。结论提示对于≤10mm、位于中下部胃且无溃疡的肿瘤,可考虑扩大ESD适应证。

要点

  • 39%超扩大适应证的早期胃癌术后病理为内镜治愈性A/B级,可仅用ESD治愈。
  • 肿瘤≤10mm、无溃疡、分化型、位于胃远端三分之二为内镜治愈性A/B级的独立预测因素。
  • 符合上述特征的≤10mm无溃疡中下部胃肿瘤可考虑ESD治疗。

核心结论

  • 对于术前评估超出ESD扩大适应证的早期胃癌患者,部分肿瘤可通过增加肿瘤部位至ESD适应证而接受ESD治疗。

研究设计与样本

  • 回顾性队列研究,纳入2006年至2016年673例术前评估超出ESD扩大适应证并接受胃切除术的早期胃癌患者。

主要发现

  • 39%(263/673)接受胃切除术的患者术后病理为内镜治愈性A或B级(eCuraA/B),可仅通过ESD治愈。
  • 多因素分析显示,术前评估肿瘤大小≤10mm(OR 0.240;95%CI=0.12-0.46)、无溃疡(OR 0.500;95%CI=0.29-0.87)、分化型组织学(OR 0.599;95%CI=0.43-0.84)及位于胃远端三分之二(OR 0.499;95%CI=0.28-0.88)为eCuraA/B的独立预测因素。
  • 在分化型/未分化型、肿瘤≤10mm、位于胃远端三分之二且无溃疡的患者中,分别有63.6%(7/11)和61.3%(19/31)被判定为eCuraA/B。

关键数值与推荐

  • 肿瘤大小≤10mm、无溃疡、分化型组织学、位于胃远端三分之二为eCuraA/B的独立预测因素。
  • 对于分化型或未分化型、肿瘤≤10mm、位于胃远端三分之二且无溃疡的患者,eCuraA/B比例分别为63.6%(7/11)和61.3%(19/31)。

临床怎么用

  • 对于肿瘤≤10mm、位于胃中下部且无溃疡的早期胃癌患者,可考虑将肿瘤部位纳入ESD适应证,尝试ESD治疗。

局限性

  • 本研究为回顾性研究,样本来自单中心,结论需前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Endoscopic submucosal dissection (ESD) application for patients with tumors beyond the expanded indication for ESD is inconclusive. This study aimed to identify the preoperative clinical features that can be curatively treated with ESD in patients with early gastric cancer (EGC) beyond the indication of ESD. METHODS: From 2006 to 2016, 673 patients who underwent gastrectomy for EGC beyond the expanded indication for ESD based on preoperative assessments were retrospectively reviewed. We identified tumors curatively resected by ESD based on the postoperative pathologic findings. We also analyzed the clinical and pre-treatment features to determine the risk factors associated with curative resection of ESD. RESULTS: 39% of the patients (263/673) who had undergone gastrectomy had tumors of endoscopic curability A or B (eCuraA/B) that could be treated by ESD alone. In multivariate analysis, tumor size ≤ 10 mm (OR 0.240; 95% CI = 0.12-0.46), no ulceration (OR 0.500; 95% CI = 0.29-0.87), differentiated histology (OR 0.599; 95% CI = 0.43-0.84), and location in the distal two-thirds of the stomach (OR 0.499; 95% CI = 0.28-0.88) in pre-treatment assessment were identified as independent predictors of eCuraA/B. Considering the risk factors, 63.6% (7/11)/61.3% (19/31) of patients with a differentiated/undifferentiated tumor size ≤ 10 mm located in distal two-third of the stomach without ulceration were deemed as eCuraA/B. CONCLUSIONS: This study suggests that patients with EGC indicated for surgery can be treated by ESD by adding tumor locations in the indication for ESD. Thus, ESD can be applied for patients with a tumor size ≤ 10 mm located in the lower/middle stomach without ulceration.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Song JH, Lee S, Park SH, et al. Applicability of endoscopic submucosal dissection for patients with early gastric cancer beyond the expanded indication for endoscopic submucosal dissection. Surg Endosc. 2022. PMID: 35546209. doi:10.1007/s00464-022-09288-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。